Diagnóstica Longwood
  • esES
  • +34 976 320 638
  • M-T: 8.30-17.30 F:8.30-14.30
  • Catalog
    • Immunology and transplantation
      • HLA Typing
      • Allergy
      • Alloantibodies Detection
      • HLA-associated diseases
      • Chimerism
      • Immune response and biomarkers
      • Immunosequencing
      • Other – Immunology
    • Molecular Genetics
      • Cystic Fibrosis
      • Prenatal Diagnosis
      • Reproduction
      • Pharmacogenomics
      • Triplet Expansion
      • Genetic Panels
      • Other – Genetics
    • Hematology and blood bank
      • Blood Group Genotyping (RBC)
      • Platelet Antibody Testing
      • Thrombophilias and Hemochromatosis
      • Cryopreservation
      • Other – Hematology
    • Oncology
      • Solid Tumor
      • Oncohematology
    • Microbiology
      • Virus
      • Bacteria
      • Fungus
      • Metatranscriptomics
      • CMI Quick-Sepsis
      • DNA/RNA extraction
    • Preanalytics
      • Blood collection
      • Sampling and Extraction
      • Sample transportation
  • Company
    • Contact
    • Work with us
    • Our brands
  • Events
Login

myChoice CDx

CatalogOncologySolid Tumor

The most comprehensive tumor test to determine Homologous Recombination Deficiency (HDR) Status by studying the BRCA genes in patients with ovarian cancer.

myChoice CDx is the first FDA-approved in vitro diagnostic test to determine Homologous Recombination Deficiency (HRD) status by NGS in patients with ovarian cancer.

Homologous recombination is the mechanism by which DNA damage is repaired. When homologous recombination is not able to fix the damaged DNA, it is called Homologous Recombination Deficiency. Approximately 50% of all ovarian cancer tumors have HRD. HRD status is determined by analyzing the tumor for mutations in the BRCA1 and BRCA2 genes and then by measuring genomic instability. If there is a mutation in the BRCA1 or BRCA2 genes, or the measure of genomic instability is above a certain level (42), it is considered HRD positive (HRD+).

If the tumor is HRD+, it is more likely to respond to agents that block DNA repair, such as PARP (Poly ADP ribose polymerase) inhibitors (Olapariby Bevacizumab), than those tumors without genomic instability. When DNA damage cannot be corrected, cancer cells are killed, and tumor growth is slowed or even reversed. Thus, with myChoice CDx it is possible to evaluate the benefit of PARP inhibitor therapy in patients.

myChoice CDx enables the detection and classification of single nucleotide variants, insertions and deletions, and large rearrangements in the protein coding regions and intron/exon boundaries of BRCA1 and BRCA2 genes, as well as the calculation of the Genomic Instability Score (GIS) using an algorithm that takes into account Loss Of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI) and Large-Scale Transitions (LST).

It is the only commercially available tumor test designed to detect large rearrangements, which account for 5% of all ovarian cancer mutations.

Key features:

  • Robustness
  • Accuracy
  • Reproducibility
  • Easy-to-interpret results

Service

Service performed in the United States. FFPE samples with an area ≥25mm2 containing 40 µm of tumour will be collected. The ideal sample should have ≥30% tumour.
Area of tumor (mm2)# of 5 µm unstained slides
20-258
15-1912
10-1416
5-920

Public Documentation

  • Flyer myChoice CDx PLUS_EN_02_21_V3
  • Flyer myChoice CDx PLUS_EN_06_2021

Related products

Verogen PrepStation

Robot for the generation of high-quality ForenSeq libraries, minimising errors and hands-on time. Ahorra recursos y minimiza los errores humanos con la PrepStation de Verogen. Esta plataforma, diseñada y validada Free up resources and minimise human error with the Verogen PrepStation. Designed and validated specifically for semi-automated MPS (Massive Parallel Sequencing) library preparation with ForenSeq […]
  • Certificado RUO

Urinary Pathogen ID/AMR Panel (UPIP)

NGS capture kit that allows detection and quantification of more than 170 organisms, including common and rare main uropathogens. In addition, it includes the detection of more than 3,700 antimicrobial resistance markers. UPIP is a NGS research panel that brings the power of precision metagenomics to the identification of genitourinary pathogens. This capture kit that […]
  • Certificado RUO

Prolaris®

Prognostic test to determine tumour aggressiveness and 10-year disease-specific mortality in patients with primary localised prostate cancer.
  • Certificado CE
  • Certificado IVD
Oncología molecular

Oncology

Myriad Genetics
  • Certificado CE
  • Certificado IVD
  • Next Generation Sequencing (NGS)
Request information - myChoice CDx

    Contact with the commercial department of Diagnóstica Longwood to request information and you will allow us to contact you commercially by email or telephone, complying with the European Data Protection regulations.

    You can unsubscribe when you want, rectify or limit your data.



    I consent to the use of my data to receive information and news

    In compliance with the provisions in the regulation General of protection of data 2016/679, DIAGNOSTICA LONGWOOD informs that its e-mail address, as well as other personal data that may be included in this form form part of a treatment of personal data whose features are detailed below: The controller of such processing will be DIAGNOSTICA LONGWOOD and the purpose will be to answer the queries raised by the user and to send him/her requested information, as well as to send information and news about our company, in case he/she has authorised it. By marking the consent, you are legitimising this use. DIAGNOSTICA LONGWOOD does not pass on data to third parties. You may at any time exercise your rights of access, rectification and deletion of your data, as explained in our Privacy Policy.


    Product families

    • Molecular Genetics
      • Prenatal Diagnosis
      • Triplet Expansion
      • Pharmacogenomics
      • Cystic Fibrosis
      • Other – Genetics
      • Genetic Panels
      • Reproduction
    • Hematology and blood bank
      • Platelet Antibody Testing
      • Cryopreservation
      • Blood Group Genotyping (RBC)
      • Other – Hematology
      • Thrombophilias and Hemochromatosis
    • Immunology and transplantation
      • Alloantibodies Detection
      • HLA-associated diseases
      • Immunosequencing
      • Other – Immunology
      • Chimerism
      • Immune response and biomarkers
      • HLA Typing
    • Microbiology
      • Virus
      • Fungus
      • DNA/RNA extraction
      • CMI Quick-Sepsis
      • Metatranscriptomics
    • Oncology
      • Oncohematology
      • Solid Tumor
    • Preanalytics
      • Sampling and Extraction
      • Blood collection
      • Sample transportation

    Diagnostica Longwood

    Customer Service:
    M-T 8.30 – 17.30 / F 8.30 – 14.30
    +34 976 320 638 – info@dlongwood.com

    • Quality Policy
    • Legal Warning
    • Privacy Policy
    • Cookie policy
    • Data Protection

    2021 © Diagnóstica Longwood SL

    We are using cookies to give you the best experience on our website.

    You can find out more about which cookies we are using or switch them off in settings.

    Powered by  GDPR Cookie Compliance
    Privacy Overview

    This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

    Strictly Necessary Cookies

    Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

    If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

    3rd Party Cookies

    This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

    Keeping this cookie enabled helps us to improve our website.

    Please enable Strictly Necessary Cookies first so that we can save your preferences!

    Política de cookies

    Más información sobre nuestra política de cookies